Waldenström's macroglobulinemia: Difference between revisions

Jump to navigation Jump to search
Mirdula Sharma (talk | contribs)
No edit summary
Mirdula Sharma (talk | contribs)
Line 11: Line 11:


==[[Waldenström's macroglobulinemia historical perspective|Historical Perspective]]==
==[[Waldenström's macroglobulinemia historical perspective|Historical Perspective]]==
* Waldenström's macroglobulinemia was first discovered by Jan G. Waldenström, a Swedish physician in 1944 in two patients with bleeding from the nose and mouth, anemia, decreased levels of fibrinogen in the blood (hypofibrinogenemia), swollen lymph nodes, neoplastic plasma cells in bone marrow, and increased viscosity of the blood due to increased levels of a class of heavy proteins called macroglobulins.<ref name="wiki"/>


==[[Waldenström's macroglobulinemia classification|Classification]]==
==[[Waldenström's macroglobulinemia classification|Classification]]==

Revision as of 19:35, 6 November 2015


Waldenström's macroglobulinemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Waldenström's macroglobulinemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Bone Marrow Aspiration and Biopsy

Electrophoresis and Immunofixation

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Waldenström's macroglobulinemia On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Waldenström's macroglobulinemia

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Waldenström's macroglobulinemia

CDC on Waldenström's macroglobulinemia

Waldenström's macroglobulinemia in the news

Blogs on Waldenström's macroglobulinemia

Directions to Hospitals Treating Waldenström's macroglobulinemia

Risk calculators and risk factors for Waldenström's macroglobulinemia

For patient information on this page, click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mirdula Sharma, MBBS [2]

Synonyms and keywords: Primary macroglobulinemia; B-cell lymphoproliferative disease; Lymphoplasmacytoid lymphoma, Lymphoplasmacytoid Lymphomas; Macroglobulinemia; Plasmacytoid lymphocytic lymphoma; Familial Waldenstrom's Macroglobulinaemia; Familial Waldenstrom Macroglobulinaemia

Overview

Historical Perspective

Classification

The World Health Organization placed Waldenström's macroglobulinemia under the category of lymphoplasmacytic lymphomas, which is a subcategory of low-grade Non-Hodgkin lymphoma.[1]


Pathophysiology

Causes

  • The most common causes are a somatic mutation in MYD88 (90% of patients) and a somatic mutation in CXCR4 (27% of patients).[1]

Differentiating Waldenström's macroglobulinemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Bone Marrow Aspiration and Biopsy | Electrophoresis and Immunofixation | Chest X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1




Template:WikiDoc Sources

  1. 1.0 1.1